Stockreport

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]

PMV Pharmaceuticals, Inc.  (PMVP) 
PDF therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type, remains on track to initiate in Q1 2024 Phase 1 analysis from the PYNNACL [Read more]